Advertisement
Canada markets open in 52 minutes
  • S&P/TSX

    21,728.55
    +14.01 (+0.06%)
     
  • S&P 500

    5,018.39
    -17.30 (-0.34%)
     
  • DOW

    37,903.29
    +87.37 (+0.23%)
     
  • CAD/USD

    0.7293
    +0.0012 (+0.16%)
     
  • CRUDE OIL

    79.65
    +0.65 (+0.82%)
     
  • Bitcoin CAD

    80,618.05
    +890.80 (+1.12%)
     
  • CMC Crypto 200

    1,272.33
    +1.58 (+0.12%)
     
  • GOLD FUTURES

    2,312.00
    +1.00 (+0.04%)
     
  • RUSSELL 2000

    1,980.23
    +6.32 (+0.32%)
     
  • 10-Yr Bond

    4.6100
    +0.0150 (+0.33%)
     
  • NASDAQ futures

    17,582.50
    +144.25 (+0.83%)
     
  • VOLATILITY

    15.05
    -0.34 (-2.21%)
     
  • FTSE

    8,154.67
    +33.43 (+0.41%)
     
  • NIKKEI 225

    38,236.07
    -37.98 (-0.10%)
     
  • CAD/EUR

    0.6812
    +0.0019 (+0.28%)
     

Amneal to Report First Quarter 2024 Results on May 3, 2024

BRIDGEWATER, N.J., April 10, 2024--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) announced today that the Company will release its first quarter 2024 financial results on Friday, May 3, 2024, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time.

The financial results and live webcast will be accessible through the Investor Relations section of the Company's website at https://investors.amneal.com.

Individuals may register for the conference call by clicking the link here. Once registered, participants will receive dial-in details and unique PIN which will allow them to access the call.

ADVERTISEMENT

To access the call through a conference line, dial 1 (833) 470-1428 (in the U.S.) or for a list of toll-free international numbers, visit this link. The access code for the call is 172198.

A replay of the conference call will be posted shortly after the call and will be available for seven days.

About Amneal
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX), headquartered in Bridgewater, NJ, is a global pharmaceuticals company. We make healthy possible through the development, manufacturing, and distribution of a diverse portfolio of over 270 pharmaceutical products, primarily within the United States. In its Generics segment, the Company is expanding across a broad range of complex product categories and therapeutic areas, including injectables and biosimilars. In its Specialty segment, Amneal has a growing portfolio of branded pharmaceuticals focused primarily on central nervous system and endocrine disorders, with a pipeline focused on unmet needs. Through its AvKARE segment, the Company is a distributor of pharmaceuticals and other products for the U.S. federal government, retail, and institutional markets. For more information, please visit www.amneal.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240410515765/en/

Contacts

Investor Contact
Anthony DiMeo
Head of Investor Relations
anthony.dimeo@amneal.com